Keros Therapeutics (KROS) Projected to Announce Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is projected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.96) per share and revenue of $14.76 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, analysts expect Keros Therapeutics to post ($5.27) EPS for the current fiscal year and ($6.39) EPS for the next fiscal year.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $11.04 on Monday. The business’s 50-day moving average is $11.27 and its 200 day moving average is $12.14. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The company has a market capitalization of $218.92 million, a P/E ratio of -2.98 and a beta of 1.13.

Keros Therapeutics declared that its board has approved a stock repurchase program on Wednesday, September 9th that permits the company to repurchase $5 million in shares. This buyback authorization permits the company to repurchase up to 2.3% of its shares through open market purchases. Share buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. This represents a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 5,343 shares of company stock worth $54,985. Insiders own 12.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on KROS shares. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Wells Fargo & Company reduced their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Finally, Leerink Partners dropped their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.